M-Biotech has received a third U.S. patent for its unique hydrogel technology used in its implantable glucose biosensor. The M-Biotech biosensor was developed to overcome the pain and inconvenience of existing "finger stick" products that dominate the market and result in unacceptable levels of non-compliance with diabetic patients.

There are two main parts to the M-Biotech system: the implantable glucose biosensor, which is a tiny sensor that is implanted near the abdomen in the subcutaneous layer of the skin and the pager like alarm monitoring device that displays glucose levels to the patient, and alerts them when the levels are not safe so corrective action can be taken.

"The implanted sensor is what makes our system radically different from other approaches now being pursued," said In Suk Han, President & CEO of M-Biotech. "Our sensor's technology is very simple, inexpensive, and completely eliminates the main hurdles that face both chemical and optical methods such as calibration, long term implantation, interference, and longevity. In addition, the advances allowed by the M-Biotech sensor could enable the development of the first closed-loop insulin delivery system because you could now have a wireless connection between a highly reliable continuous glucose monitor (M-Biotech device) and a topical or implanted insulin delivery system now under development by several companies."

M-Biotech is a development stage company based in Salt Lake City, Utah with issued patents (both domestic and international) for its core hydrogel technology, and has several patents pending. The company has secured initial funding from Chong Kun Dang, a large Korean based pharmaceutical company, and is seeking strategic partners to assist with animal and human clinical studies, production, and sales and marketing of the final product.